The heart is nearly unique in the body in that it has a constant workload well beyond the normal maintenance of cellular integrity. In addition, the heart of a large animal such as man also has the capacity to increase its workload by nearly 10-fold for considerable amounts of time. A high steady state and peak work demand require the heart to use the space- and weight-efficient mitochondria to provide an adequate energy conversion rate to support these activities. The heart's energy conversion results in remarkably high metabolite turnover rates (i.e., time to turnover the entire metabolite pool), with values ranging from resting to maximum workloads of 10--2 s for ATP, 170--40 ms for ADP, and 250--70 ms for mitochondrial nicotinamide adenine dinucleotide (NADH) ([@bib34]; [@bib4]). With this requirement for a constant workload coupled to large sustained changes in dynamic range, it is not surprising that cardiac energy conversion is highly specialized. As seen from the metabolic pool turnover estimates above, a slight mismatch between energy conversion rates and workload could severely impact metabolite levels in seconds. Thus, tight temporal coupling between mitochondrial energy conversion and heart workload is an absolute requirement of the metabolic control network. In addition, because oxygen extraction from the coronary vasculature is nearly complete, a tight coupling of coronary blood flow control to heart workload is important. Taking these data into consideration, it is not surprising that there is a linear relationship between the rate of mitochondrial respiration, blood flow, and workload ([@bib52]; [@bib17]).

Remarkably, the heart is able to accomplish this over a wide workload range with very little change in the steady-state concentrations of ATP, ADP, and NADH associated with this energy conversion process, despite the approximately100-ms turnover of some metabolite pools. Even the metabolites creatine phosphate (CrP) and creatine, which are associated with the creatine kinase system that is a temporal buffer of high energy phosphates ([@bib15]), remain remarkably constant. Thus, the balance of energy conversion rates with ATP hydrolysis must be precisely orchestrated over very short time constants. This ability of energetic tissues to maintain the concentration of high energy phosphates during periods of increased use has been appreciated for many years. One of the first lengthy discussions and experimental insights was provided by A.V. Hill in his 1950 "Challenge to Biochemists" ([@bib19]). Concerning the energetics of skeletal muscle, he stated, "Indeed, no change in the ATP has ever been found in living muscle except in extreme exhaustion, verging on rigor." After a discussion of the "Lohmann reaction," in which creatine kinase was believed to buffer ATP concentrations, he stated, "We should not, however, be so satisfied with the explanation of why no change in ATP is ever found in living muscle that we cease to look for it: for another possibility exists...Is it not possible that as stimulation proceeds a balance is reached at some intermediate level between breakdown and restoration?" Hill went on to propose using different animal models with different metabolic rates as part of his challenge. This proposal made by Hill will be the topic of this Perspective as it pertains to the heart. That is, I will review the current understanding of how heart mitochondria maintain a balance between the rate of ATP production (qATP) and hydrolysis while keeping the free energy available from ATP hydrolysis constant, and use some allometric relationships to contribute to the analysis.

As discussed by Hill for skeletal muscle, it has been appreciated for years that the cardiac concentration of the high energy phosphate molecules of energy metabolism, ATP and CrP, as well as the metabolic intermediates for their formation, ADP, inorganic phosphate (Pi), and creatine, are remarkably stable during physiological changes in workload. This was established in the heart using classical Wollenberger clamps or drill biopsy methods from the 1950s through the 1970s ([@bib61]; [@bib8]; [@bib37]). Later, numerous nondestructive, more reliable in vivo cardiac phosphorus-31 nuclear magnetic resonance studies in animals ([@bib5]; [@bib30]; [@bib14]; [@bib18]; [@bib49]) and humans ([@bib10]; [@bib50]; [@bib22]) confirmed that CrP, ATP, Pi, calculated ADP, and creatine were essentially constant during physiological changes in workload. However, as maximum workloads were approached ([@bib26]; [@bib63]; [@bib29]) or the tissue was metabolically compromised by ischemia, demand ischemia, different disease states, or hypoxia ([@bib18]; [@bib62], [@bib64]), the ability to maintain these metabolite concentrations was compromised. Thus, under normal physiological conditions, the mammalian heart is capable of changing qATP with little or no change in the net concentrations of ADP and Pi, which are products of ATP hydrolysis and substrates for ATP formation in oxidative phosphorylation. This was a difficult concept to accept by many because of the logical dogma of oxidative phosphorylation being paced by the feedback of ATP hydrolysis products ([@bib23]). This feedback mechanism does, apparently, come into play at high workloads ([@bib63]) or in response to artificial alterations of metabolic substrates ([@bib28]), as well as in very young animals ([@bib46]). The major limitation of the feedback system is the fundamentally limited dynamic range of using breakdown products as feedback while maintaining an adequate ΔG~ATP~ that is sufficient to support the potential energy requirements of the heart, including muscle contraction and calcium sequestration ([@bib55]). The maintenance of energy metabolite concentrations and ΔG~ATP~ available for work during changes in workload has been termed metabolic homeostasis. Homeostasis is an appropriate term because the cardiac cell energy metabolic control network seems to be programmed to maintain ΔG~ATP~ at a remarkably constant value, much like cellular volume or pH. Herein, I discuss the efforts to understand the cellular and mitochondrial control network that orchestrates the metabolic homeostasis of the heart. This begins with a discussion of the distribution of cardiac contractile and energy conversion elements within the cell.

Because of the tight coupling between energy conversion and constant cardiac contraction, is there an optimal relationship between cytosolic volume devoted to energy conversion (i.e., mitochondria) versus contractile elements (i.e., myofibrils)? Each cardiac myocyte is "designed" to meet its work, or contractile force, requirements at maximum workloads. This concept has been termed "symmorphosis" by [@bib60], logically suggesting that physiological maximum demands determine the capacity of all of the elements in a physiological system, with little or no "wasted" reserve capacity. Using this approach, the cell has a fixed requirement for the cross-sectional area of the trans-cellular contractile elements relative to its maximum power requirements. Related to this, if mitochondria have a fixed ability for qATP per unit mitochondrial volume, the mitochondrial volume required to support this activity will be fixed relative to the myofibril content. An interesting way to evaluate this relationship between contractile element and mitochondria cellular content in the mammalian left ventricle is to look across an allometric series of animals where the peak power does not change dramatically, but the resting rate can vary over an order of magnitude ([@bib59]). [@bib21] performed this analysis and remarkably found that the fractional volume of mitochondria was fixed from mouse to horse at ∼21% of the total heart mass. This was recently confirmed when the amount of cytochrome a,a~3~ or total number of cytochrome chains per gram of heart was found to be essentially identical across a similar allometric series ([@bib43]). Thus, the relationship between the cytosolic volume used for energy conversion is fixed as a function of animal size, implying an optimized ratio of cross-sectional area of muscle fibers to mitochondrial volume to support the constant metabolic needs of the mammalian heart. Surprisingly, the ratio of mitochondrial volume, or cytochrome chains, to muscle mass is also the same in the left and right heart from the same animals, even though the pressure volume work of the hearts is nearly fivefold higher in the left ventricle compared with the right chamber ([@bib42]). [@bib42] suggested that the rate of ATP use per gram of the right and left heart actually approaches the same value at maximum workload based on the slope of the respiratory rate versus rate pressure product (RPP) for the left and right ventricles. The right ventricle has a much steeper relationship between RPP and oxygen consumption than the left ventricle, which reveals very similar oxygen consumption levels when extrapolated to the maximum workload. Thus, the cytosolic fraction devoted to energy conversion and contractile apparatus of the mammalian right and left chambers are identical, and this is likely related to the same peak work requirements of the two chambers per gram of myocardium. These authors suggested that because the heart cell was already optimized with regard to mitochondrial content and contractile elements, the only way the heart can respond to chronic increases in workload and maintain metabolic homeostasis is to increase the number of cells or total cell cytoplasm, resulting in hypertrophy. This was a requirement because remodeling the energetically "balanced" cardiac cell cytoplasm would not improve efficiency or sustained power. The steep relationship between RPP and metabolic stress in the right ventricle may also explain why this chamber is more prone to hypertrophy than the left ventricle. These results on the volume distribution of cardiac mitochondria suggest that across the mammalian allometric series, and even between the left and right heart of a given animal, the fraction volume of the mitochondria and contractile elements is fixed, and it is likely optimized to provide appropriate qATP to match ATP hydrolysis by the contractile elements, and Ca^2+^ SR recycling maintains metabolic homeostasis during normal and near maximal workloads.

Given that the mitochondrial volume fraction of the mammalian cardiac myocyte is fixed, how can the mitochondria match qATP over the wide range of ATP hydrolysis without changing the kinetic or thermodynamic driving forces for ATP production? The simplest method, or Occam's razor, to accomplish this task is to simply change the maximum velocity ATP production (qATP~max~) in proportion to the ATP production demand. This remarkably simple mechanism is illustrated in [Fig. 1](#fig1){ref-type="fig"}, where a simple Michaelis--Menten model for ADP driving ATP production with a K~m~ of 30 µM with variable qATP~max~ values generates a series of \[ADP\] versus qATP curves. As seen from the green line, qATP can be altered by simply changing the qATP~max~ of the reaction while keeping ADP constant. It should be pointed out that the mitochondrial ATP production reaction is also a function of \[Pi\] and the inner mitochondrial membrane proton motive force (ΔΨ~H~), which are ignored in this simplification but will be discussed further below. It is important to note that for this mechanism to work during dynamic changes in cardiac workload, qATP~max~ cannot be simply a function of \[E\] or mitochondrial F~1~F~0~ATPase content, as in the classical Michaelis--Menten system where V~max~ = \[E\]. Because \[F~1~F~0~ATPase\] is constant in the heart with workload, the only way to alter qATP~max~ is to change enzyme kinetics via posttranslational modifications (PTMs), assuming no changes in the kinetic and thermodynamic driving forces. For the purposes of this discussion, I will refer to the theoretical qATP~max~ (qATP~maxt~) as the maximum rate of qATP only limited by \[F~1~F~0~ATPase\], whereas the observed qATPmax (qATP~maxo~) is the capacity of the enzyme as modulated by potential PTM events.

![Michaelis--Menten model for ADP driving ATP production at maximum Pi values. Each colored line represents a different V~max~ for the reaction. The V~max~ values are listed at the end of each curve. The green line represents a constant homeostatic ADP concentration.](JGP_201210783_Fig1){#fig1}

Returning to the allometric series in cardiac energy metabolism discussed above, is there evidence here that qATP~max~ is modulated? As mentioned earlier, the "resting" heart rate and workload are roughly 10 times higher in the rat than in larger animals, mostly because of its higher resting heart rate. As also discussed above, the mitochondrial or \[F~1~F~0~ATPase\] contents are nearly identical using a variety of proteomic methods ([@bib43]). Thus, if qATP~max~ was also constant, the \[ADP\] content would have to be much higher in smaller animals than in larger animals to maintain qATP equal to hydrolysis. However, the estimated in vivo \[ADP\] concentration in dog (∼55 µM) ([@bib26]) or human (estimated by [@bib9]) is similar to that in mouse (∼50 µM) ([@bib9]), or even much lower (∼13 µM) ([@bib20]). These data are inconsistent with ADP or Pi driving resting respiratory rate in large animals and small rodents. [@bib9] realized this after making these observations in the mouse and stated, "It is also tempting to speculate that a relatively constant cardiac PCr/ATP ratio and \[ADP\] across species with 10-fold differences in heart rate is consistent with the hypothesis that ADP does not control cardiac energy turnover under typical physiological conditions across mammalian species." These data imply that qATP~maxo~ is lower than qATP~maxt~ at rest in larger animals, and qATP~maxo~ may approach qATP~maxt~ at rest in active small rodents, providing the higher qATP required. Consistent with this notion, [@bib43] demonstrated that the extracted molar activity of the F~1~F~0~ATPase was higher in smaller animals compared with larger animals. These authors suggested that PTMs modulate the activity of the mitochondrial oxidative phosphorylation complexes depending on the metabolic stress (qATP/qATP~maxt~) of a given heart or tissue. These data seem to support that qATP~max~ is differentially modulated at rest in various species.

What is the evidence for dynamic regulation of qATP~maxo~? For this mechanism to work, qATP~maxo~ must be modulated after acute changes in workload. [@bib58] found a net depolarization of ΔΨ~H~, the primary driving force for qATP, whereas ADP and Pi remained essentially constant during cardiac work increases. These results agree with [@bib27], who also observed a small depolarization ΔΨ~H~ with workload. These data are consistent with nearly routine human clinical data. Using Tc-sestamibi as a monitor of mitochondrial membrane potential ([@bib44]), clinicians often observe a decrease in Tc retention consistent with a depolarization ΔΨ at near maximum exercise in humans ([@bib57]). [@bib58] concluded, "Based on these findings it was proposed that during increased cardiac work, the capacity of the mitochondrial ATP synthase was increased." Here, the "capacity of the mitochondrial ATP synthase" is equivalent to qATP~maxo~. Again, this conclusion is based on the observation that qATP increases with greater work without increases in ADP, Pi, or ΔΨ~H~. [@bib58] also attempted to measure alterations in the activity of extracted F~1~F~0~ATPase, but these were not elaborated on. However, much earlier, [@bib11], [@bib12]) found that with increases in cardiac cell work, substantial increases in the reverse ATPase reaction of the F~1~F~0~ATPase could be detected in rapidly extracted submitochondrial particles (SMPs). This reaction is of interest because the ATP hydrolysis reaction requires the complex rotation of the γ subunit, much like the ATP synthetic reaction. Thus, alterations of the hydrolysis reaction could be reflecting events that affect the synthetic reaction. Interestingly, these authors also found that these effects were apparently dependent on the increase in matrix Ca^2+^ ([@bib12]). This basic observation was repeated in heart in vivo*,* where [@bib51] showed that reversible activity increases in extracted F~1~F~0~ATPase could be detected in small biopsies collected from the beating heart that were stimulated with dobutamine. In those studies, they noted that preparation speed was critical in demonstrating the effect; it took only seconds to sonicate the biopsy to generate the SMPs and perform assays in the absence of detergents. These effects were expanded on by [@bib43], who not only evaluated the effect of animal size but also the effect of work on the in vivo porcine heart and perfused rabbit heart using native gel techniques to monitor F~1~F~0~ATPase activity instead of SMPs. These authors also found work-related alterations in extracted F~1~F~0~ATPase activity that was very sensitive to preparation time and detergents. Thus, a very labile modification of F~1~F~0~ATPase ATPase activity seems related to the activity of the state of the tissue just before extraction, which is consistent with an increase in qATP~maxo~ with workload via a dynamic PTM process.

These F~1~F~0~ATPase assays are interesting because they involve the rotation of the γ subunit within the complex; however, the effect on ATP synthesis can only be speculated. Regrettably, the only way to monitor ATP synthetic activity is to have a ΔΨ~H~ across the membrane to drive the reaction forward. Thus, this assay is only practically conducted in isolated cardiac mitochondria. The extensive purification and artificial methods of ΔΨ~H~ used in reconstituted systems is not likely to be feasible with this apparently labile system. In a series of studies, [@bib53], [@bib54]) and [@bib6] determined the effective qATP~maxo~ by monitoring the qATP via oxygen consumption in the presence of saturating \[ADP\] and \[Pi\] while monitoring ΔΨ~H~ or NADH redox state to estimate the driving force for ATP production. These studies clearly demonstrated that the cardiac mitochondria qATP~max~ can be dynamically modulated. They showed that alterations in matrix Ca^2+^ can be a major regulator of qATP~max~ by modulating F~1~F~0~ATPase activity independently of the classical Ca^2+^-dependent dehydrogenase activation ([@bib32]). These results were consistent with studies by [@bib35]; [@bib36] and [@bib39]. [@bib43] also showed that pretreating mitochondria with Ca^2+^ increased F~1~F~0~ATPase hydrolytic activity in native gels, supporting the link between in vitro ATPase assays and synthetic activity within mitochondria. Again, these activity differences were dependent on rapid sample preparation and the detergents used. From these isolated mitochondria studies, it is apparent that qATP~max~ can be modulated within isolated mitochondria and that the cytosolic signaling molecule regulating this process might be Ca^2+^, which is involved in activating muscle contraction, and Ca^2+^ sequestration in the SR is also a major energetic requirement of the cardiac cell ([@bib55]; [@bib4]).

The regulation of energy metabolism in the cardiac cell by Ca^2+^ is complex. Ca^2+^ release from the SR activates muscle contraction but also must be actively pumped back into the SR before the next contraction. The energetic cost of Ca^2+^ pumping is estimated at 10--30% of the total energy cost of muscle contraction. Some cardiac mitochondria are located in close proximity to the SR, and a local release of Ca^2+^ in these regions likely results in a high local delivery of Ca^2+^ to the mitochondria ([@bib48]), increasing the kinetics driving force for Ca^2+^ entry into the matrix. Within the matrix, Ca^2+^ clearly activates several dehydrogenases via dephosphorylation, pyruvate dehydrogenase (PDH), or poorly defined substrate affinity mechanisms ([@bib13]). This increase in dehydrogenase activity could increase the net driving force for ATP production by increasing \[NADH\] and subsequently the ΔΨ~H~. Indeed, many authors have suggested that the activation of the dehydrogenases is adequate to support the observed metabolic homeostasis in the heart with workload. Can the simple increase in delivery of NADH via the dehydrogenases activated by Ca^2+^ explain the balancing of qATP with hydrolysis in the absence of changes in ADP and Pi? The potential energy in NADH is delivered to the F~1~F~0~ATPase via the generation of ΔΨ~H~. If NADH alone was driving ATP production higher, ΔΨ~H~ would need to increase to drive qATP faster when \[ADP\], \[Pi\], and ΔG~ATP~ are fixed. How big a change in ΔΨ~H~ would have to occur to increase qATP three- to fourfold under these energy homeostatic conditions? The relationship between ΔΨ~H~ and qATP is linear over physiological rates, with a slope change of ∼1.3% in ATP production/mV ΔΨ ([@bib53]). This suggests that increasing the heart rate by threefold would require approximately an additional 150 mV over the resting value of 180 mV, taking ΔΨ to \>300 mV. Thus, driving respiration through NADH alone is very inefficient with regard to ΔΨ. Indeed, as discussed above, most of the current evidence suggests that ΔΨ decreases with increasing workload, which would decrease the driving force for ATP production, not increase it. Thus, a model that only uses alterations in NADH and/or ΔΨ caused by modulation of dehydrogenase activity is not consistent with experimental results. Clearly, the activation of NADH generation by Ca^2+^ must be coupled to other "downstream" events in oxidative phosphorylation to be effective in maintaining metabolic homeostasis. Many studies have suggested that Ca^2+^ is key in maintaining cardiac metabolic homeostasis. The best piece of evidence is the observation that blocking Ca^2+^ entry into mitochondria disrupts metabolic homeostasis in working tissues ([@bib25]; [@bib56]; [@bib31]). Thus, if Ca^2+^ is the key cytosolic signaling molecule linking workload and mitochondria energy conversion, it is likely that it acts on more than just dehydrogenase reactions ([@bib4]; [@bib16]).

How are other matrix elements involved in the oxidative generation of ATP dynamically modified by Ca^2+^ or other transducers? The role of PTM in the regulation of NADH generation is well established, especially for the PDH reaction. Clearly, the effects of workload on the extracted F~1~F~0~ATPase ([@bib12]; [@bib51]; [@bib43]) and the effects of Ca^2+^ on isolated mitochondria qATP~max~ ([@bib53]) independent of dehydrogenase activation point to a role for a dynamic PTM system regulating the elements of ATP production well downstream of NADH generation. However, the specific mechanisms for this apparently labile PTM modulation of F~1~F~0~ATPase activity, as well as other elements in oxidative phosphorylation, remain obscure. Over the last several years, hundreds of PTM sites including phosphorylation, acylation, oxidation, and nitrosylation have been found in the oxidative phosphorylation complexes. The significance of these sites with regard to the mole fraction of protein affected and the functional consequences of modification are also poorly defined. The phosphorylation events on Complex IV ([@bib1]) and cytochrome c ([@bib40]) have been reasonably correlated with functional alterations, but the exact understanding of the kinase and phosphatase systems and their relationship with cardiac workload is unknown. The mitochondrial matrix kinase--phosphatase system is particularly puzzling. The evidence that many classical cytosolic protein kinases are present and recruited to the mitochondrial interspace is compelling ([@bib2]; [@bib33]). However, the evidence that any of these are in the matrix space is less than convincing at this stage, although ^32^P-labeling studies of mitochondria clearly show matrix kinase activity ([@bib3]). Interestingly, the PDH and branched-chain dehydrogenase kinases that are clearly present in the matrix have more sequence homology with bacterial histidine kinases than with their cytoplasmic functional relatives ([@bib45]). Several properties of the bacterial phosphorylation system are apparently present in the matrix protein phosphorylation system. These include autophosphorylation ([@bib41]), pH sensitivity ([@bib47]; [@bib3]), and highly labile nature (discussed above). The presence of these bacterial systems in mammalian tissues is gaining recognition ([@bib7]; [@bib24]) and should be more seriously considered in the mitochondria, where remnants of most of the bacterial systems remain key elements in their functionality ([@bib38]).

In summary, a very specific relationship between mitochondria and myofibril content of the mammalian heart exists across species and between heart chambers. This specific relationship likely reflects the necessity of a constant supply of ATP to the myofibrils at maximum workloads, locking in the relationship between mitochondrial and myofibril volumes. It has been appreciated for years that the heart is capable of altering qATP with ATP hydrolysis without large swings in \[NADH\], \[ATP\], \[ADP\], and \[Pi\], but small alterations in ΔΨ. This results in a metabolic homeostasis for most of the driving forces for ATP production over a wide range of physiological workloads. The simplest hypothesis for explaining these results is that qATP~max~ is dynamically modulated through reversible PTMs, including the regulation of dehydrogenases and other elements of oxidative phosphorylation and especially F~1~F~0~ATPase. A small drop in ΔΨ likely drives reducing equivalents to the high gain cytochrome oxidase system, which supports the required increase reducing equivalent removal by oxygen, but also reflects the lack of an increase in driving force for ATP production by simply increasing NADH production. It is important to note that these results are not consistent with a simple alteration in dehydrogenase activity to explain the observed metabolic homeostasis. A significant modification of qATP~max~ kinetics is still required. The evidence that qATP~max~ modulated by PTMs, which are potentially regulated by matrix Ca^2+^, is intriguing but still indirect through monitoring the driving forces of the reaction or from extracted biopsy data evaluating ATP hydrolysis activity. Although the alterations in reaction kinetics are consistent with PTM events, the definitive identification of these sites remains elusive. Growing evidence suggests that a closer look at the potential role of unconventional bacterial PTMs, which are much more difficult to detect than conventional PTM sites, might illuminate new mechanisms for the dynamic matrix regulatory events that contribute to the metabolic homeostasis of the heart.
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